Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
Weill Medical College of Cornell University
Broad Institute of MIT and Harvard
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic Prostate Cancer Patients:
Adult male ≥ 18 years of age
Patients with histologically confirmed prostate cancer at MSKCC
Progressive disease manifest by either:
Imaging modalities:
Bone Scan: New osseous lesions on bone scan and/or
MRI or CT: An increase in measurable soft tissue disease or the appearance of new sites of disease.
OR
Biochemical progression:
At least 3 rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements obtained 2 or more weeks apart. The increase over the range of values should be at least 25%.
Visible lesions by CT, bone scan, or MRI that are consistent with disease
Performance status of 60 or higher (Karnofsky scale) (Appendix B)
Ability to understand and willingness to sign a written informed consent document
Rising PSA Prostate Cancer Patients:
Adult male ≥18 years of age
Patients with histologically confirmed prostate cancer at MSKCC
Undergone radical prostatectomy
Detectable PSA (\>0.05 ng/mL) that rises on subsequent evaluation
Radiographic evaluation involving bone imaging and cross sectional imaging of at least the pelvis that is negative or equivocal for metastatic disease
Performance status of 60 or higher (Karnofsky scale) (Appendix B)
Ability to understand and willingness to sign a written informed consent document
You may not be if
Patients meeting any of the following criteria will not be eligible for study entry (Metastatic and Rising PSA cohorts):
Previous anaphylactic reaction to either J591 or FDG
Hepatic laboratory values
Bilirubin \> 1.5 x ULN (institutional upper limits of normal) Exception: patient's with a history of Gilbert's disease
